Episode Details

Back to Episodes
Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings

Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings

Published 2 months, 3 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/gene-based-interventions-for-myocilin-associated-glaucoma-august-2026-first-in-human-learnings

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings Evidence reviewed through August 24, 2026 Introduction Gene-based treatment for myocilin-associated glaucoma has moved from laboratory research into early human testing. The leading approach, called BD113, uses a virus-like particle to deliver a preassembled gene-editing system into the eye. Its goal is to disrupt the harmful form of the MYOC gene in the trabecular meshwork—the drainage tissue responsible for removing fluid from the eye. The early news is encouraging but extremely limited. A 2026 conference abstract reported sustained intraocular pressure reduction in one first-in-human participant without reported ocular or immune adverse events. A separate 2026 scientific review referred to two treated patients with normalized pressure and discontinuation of pressure-lowering medications. However, the full patient-level data—including exact pressure readings, duration of follow-up, visual-field results, editing measurements, and statistical analysis—have not been publicly reported. APAO 2026 abstract book Theranostics review () This distinction matters: a promising first human signal is not the same as proof of safety or effectiveness. As of August 24, 2026, the official ClinicalTrials.gov record still shows no posted study results and lists the trial’s status as unknown, although its last known status was recruiting. The original estimated study-completion date was December 2025. ClinicalTrials.gov: NCT06465537 () Why MYOC Is an Attractive Gene-therapy Target The MYOC gene provides instructions for making myocilin, a protein found in the trabecular meshwork and other eye tissues. Certain harmful MYOC variants cause the protein to fold incorrectly. The abnormal protein can accumulate inside trabecular meshwork cells, trigger stress in the endoplasmic reticulum, damage the cells, and reduce aqueous-fluid drainage. The result is often high intraocular pressure and progressive optic-nerve damage. Myocilin misfolding and glaucoma: a 20-year update CRISPR-Cas9-based treatment of myocilin-associated glaucoma () MYOC-related glaucoma is commonly inherited in an autosomal dominant pattern. It can cause juvenile-onset open-angle glaucoma, often with very high pressure at a young age, or adult-onset primary open-angle glaucoma. MYOC variants are estimated to account for approximately 3% to 4% of primary open-angle glaucoma and around 10% of juvenile-onset open-angle glaucoma, although the percentage varies among populations and study groups. MedlinePlus Genetics: MYOC APAO 2026 abstract book () The therapeutic logic is unusual. Many gene therapies replace a missing or defective gene. In MYOC-associated glaucoma, the proposed treatment instead aims to remove or silence a toxic, overactive gene product. Laboratory and animal studies support this strategy: disrupting mutant MYOC reduced abnormal protein accumulation, eased cellular stress, improved fluid outflow, lowered pressure, and preserved retinal ganglion cells in mouse models. CRISPR-Cas9-based treatment of myocilin-associated glaucoma () What Was Reported in Humans by August 2026? BD113: The Directly MYOC-Targeted Program BD113 is described in the clinical registry as an integration-defective lentiviral-derived virus-like par

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us